Oesophageal Cancer Trial, Recruiting NCT07272382 Sponsor: Fudan University Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT07272382
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who are well enough to carry out daily activities (assessed using a standard medical scale called ECOG, with a score of 0, 1, or 2)
  • People with esophageal (food pipe) cancer that has come back or spread, confirmed through a tissue sample, including those diagnosed at an advanced stage from the start or those whose cancer returned after earlier treatment
  • People who have never received a type of immunotherapy called a PD-1 inhibitor, or those who stopped PD-1 inhibitor treatment more than 3 months ago and whose cancer later came back (not those whose cancer failed to respond to PD-1 treatment in the first place)
  • People whose heart, liver, kidneys, and blood counts are working at levels that meet the trial's requirements
  • Women who could become pregnant must have a negative pregnancy test and agree to use effective contraception during the trial
  • People who have read and signed a consent form agreeing to take part

Who may not be able to join:

  • People whose cancer did not respond to, or stopped responding to, a previous PD-1 inhibitor treatment
  • People who have, or are strongly suspected to have, a hole or abnormal opening in the esophagus (called a fistula)
  • People with an active autoimmune disease or a condition that weakens the immune system and requires ongoing treatment (some exceptions may apply — confirm with trial site)
  • People who need to take corticosteroids or other immune-suppressing medicines regularly (low-dose or topical steroids used on the skin may be allowed — confirm with trial site)
  • People who have a history of, or currently have, a lung condition involving inflammation or scarring (interstitial lung disease or pneumonitis)
  • People with serious, uncontrolled heart problems, such as significant heart failure, unstable chest pain, a recent heart attack, or uncontrolled irregular heartbeats
  • People with a serious active infection, including active tuberculosis (TB), or viral hepatitis (hepatitis B or C) that is not adequately controlled
  • People who are pregnant or breastfeeding
  • People who have had a major operation recently, or who have a high risk of bleeding or are on blood-thinning medication in a way that may not be compatible with the trial treatment (confirm with trial site)
  • People with any other health condition that, in the treating doctor's judgement, would make it unsafe or not possible for them to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 021-64175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 June 2025
Est. completion
5 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in Skeletal Muscle Index (ΔSMI) From Baseline to 6 Months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov